BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38777866)

  • 1. A novel subtype based on driver methylation-transcription in lung adenocarcinoma.
    Wang X; Xu Z; Zhao S; Song J; Yu Y; Yang H; Hou Y
    J Cancer Res Clin Oncol; 2024 May; 150(5):269. PubMed ID: 38777866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
    Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
    Front Immunol; 2021; 12():723172. PubMed ID: 34539658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments.
    Fukuda H; Arai K; Mizuno H; Nishito Y; Motoi N; Arai Y; Hiraoka N; Shibata T; Sonobe Y; Kayukawa Y; Hashimoto E; Takahashi M; Fujii E; Maruyama T; Kuwabara K; Nishizawa T; Mizoguchi Y; Yoshida Y; Watanabe SI; Yamashita M; Kitano S; Sakamoto H; Nagata Y; Mitsumori R; Ozaki K; Niida S; Kanai Y; Hirayama A; Soga T; Tsukada K; Yabuki N; Shimada M; Kitazawa T; Natori O; Sawada N; Kato A; Yoshida T; Yasuda K; Ochiai A; Tsunoda H; Aoki K
    Cancer Sci; 2024 Jun; 115(6):1763-1777. PubMed ID: 38527308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-omics analysis of genomics, epigenomics and transcriptomics for molecular subtypes and core genes for lung adenocarcinoma.
    Zhao Y; Gao Y; Xu X; Zhou J; Wang H
    BMC Cancer; 2021 Mar; 21(1):257. PubMed ID: 33750346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Prognostic DNA Methylation Signatures in Lung Adenocarcinoma.
    Wang P; Xu G; Gao E; Xu Y; Liang L; Jiang G; Duan L
    Oxid Med Cell Longev; 2022; 2022():8802303. PubMed ID: 35814273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.
    Yang K; Wu Y
    BMC Cancer; 2021 Feb; 21(1):128. PubMed ID: 33549049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of RNA Methylation Modification-immune-related lncRNA Molecular Subtypes and Prognostic Scoring System in Lung Adenocarcinoma.
    Wang J; Shu J
    Curr Med Chem; 2024; 31(12):1539-1560. PubMed ID: 37680151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive molecular analyses of cuproptosis-related genes with regard to prognosis, immune landscape, and response to immune checkpoint blockers in lung adenocarcinoma.
    Li R; Tong R; Zhang JL; Zhang Z; Deng M; Hou G
    J Cancer Res Clin Oncol; 2024 May; 150(5):246. PubMed ID: 38722401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular subtypes based on ferroptosis-related genes and tumor microenvironment infiltration characterization in lung adenocarcinoma.
    Zhang W; Yao S; Huang H; Zhou H; Zhou H; Wei Q; Bian T; Sun H; Li X; Zhang J; Liu Y
    Oncoimmunology; 2021; 10(1):1959977. PubMed ID: 34527427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA methylation-based lung adenocarcinoma subtypes can predict prognosis, recurrence, and immunotherapeutic implications.
    Xu F; He L; Zhan X; Chen J; Xu H; Huang X; Li Y; Zheng X; Lin L; Chen Y
    Aging (Albany NY); 2020 Nov; 12(24):25275-25293. PubMed ID: 33234739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-omics analysis of m
    Wu X; Bai Z
    Sci Rep; 2021 Oct; 11(1):20921. PubMed ID: 34686691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and Validation of a DNA Methylation-related Classifier of Circulating Tumour Cells to Predict Prognosis and to provide a therapeutic strategy in Lung Adenocarcinoma.
    Gu X; Huang X; Zhang X; Wang C
    Int J Biol Sci; 2022; 18(13):4984-5000. PubMed ID: 35982906
    [No Abstract]   [Full Text] [Related]  

  • 14. The EMT-Related Genes GALNT3 and OAS1 are Associated with Immune Cell Infiltration and Poor Prognosis in Lung Adenocarcinoma.
    Luo D; Fang M; Shao L; Wang J; Liang Y; Chen M; Gui X; Yan J; Wang W; Yu L; Fan X; Wu Q
    Front Biosci (Landmark Ed); 2023 Oct; 28(10):271. PubMed ID: 37919050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and validation of tumor environment phenotypes in lung adenocarcinoma by integrative genome-scale analysis.
    Bi G; Chen Z; Yang X; Liang J; Hu Z; Bian Y; Sui Q; Li R; Zhan C; Fan H
    Cancer Immunol Immunother; 2020 Jul; 69(7):1293-1305. PubMed ID: 32189030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRT8 and KRT19, associated with EMT, are hypomethylated and overexpressed in lung adenocarcinoma and link to unfavorable prognosis.
    Wang W; He J; Lu H; Kong Q; Lin S
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32519739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mining the Prognostic Role of DNA Methylation Heterogeneity in Lung Adenocarcinoma.
    Liao H; Luo X; Huang Y; Yang X; Zheng Y; Qin X; Tan J; Shen P; Tian R; Cai W; Shi X; Deng X
    Dis Markers; 2022; 2022():9389372. PubMed ID: 35677637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SPOCK1, as a potential prognostic and therapeutic biomarker for lung adenocarcinoma, is associated with epithelial-mesenchymal transition and immune evasion.
    Liu Y; Han T; Wu J; Zhou J; Guo J; Miao R; Xu Z; Xing Y; Bai Y; Hu D
    J Transl Med; 2023 Dec; 21(1):909. PubMed ID: 38087364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction and Validation of a Tumor Microenvironment-Based Scoring System to Evaluate Prognosis and Response to Immune Checkpoint Inhibitor Therapy in Lung Adenocarcinoma Patients.
    Huang P; Xu L; Jin M; Li L; Ke Y; Zhang M; Zhang K; Lu K; Huang G
    Genes (Basel); 2022 May; 13(6):. PubMed ID: 35741714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cystatin SN promotes epithelial-mesenchymal transition and serves as a prognostic biomarker in lung adenocarcinoma.
    Yang J; Luo G; Li C; Zhao Z; Ju S; Li Q; Chen Z; Ding C; Tong X; Zhao J
    BMC Cancer; 2022 May; 22(1):589. PubMed ID: 35637432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.